With the goal of protecting patients at the forefront, we know that there is a better way to lower costs while preserving access to lifesaving medicines and treatments.
ICYMI: PhRMA CEO Stephen J. Ubl spotlights lessons learned during COVID-19.
This week, PhRMA sponsored The Washington Post’s event, Coronavirus: Lessons of the Pandemic, where PhRMA president and CEO Stephen J. Ubl shared crucial lessons learned from the pandemic on how to protect patient access to medicine and ensure the health of our robust supply chain. The event also featured PhRMA board member and Genentech CEO Alexander Hardy, who discussed Genentech’s progress during the pandemic and how to improve health equity.
Over the past two years, the biopharmaceutical industry saw success in the use of new technologies, such as the use of the mRNA platform. The industry also saw a need for policy reforms, like the Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act, to create desperately needed incentives to ensure the availability of critical-need antimicrobial products and encourage the development of new antimicrobial medicines for the future.
Yet policy proposals being discussed in Congress, such as government price setting, could have a chilling effect on crucial research and development. With the goal of protecting patients at the forefront, we know that there is a better way to lower costs while preserving access to lifesaving medicines and treatments. Further, we also must preserve the health of our supply chain while ensuring disruptions are avoided – especially during times of crisis.
